Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 37

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 37
---
isable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder Approval will not be required and the Series B-1 Common Warrants will be exercisable on the Initial Exercise Date, at an assumed exercise price equal to $1.30 (equal to the assumed combined public offering price per share of Common Stock and accompanying Common Warrants). The Series B-1 Common Warrants will expire five years from the Initial Exercise Date or the Warrant Stockholder Approval, as applicable. The exercise price and number of shares of Common Stock issuable upon exercise of the Series B-1 Common Warrants are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock.

#### Exercisability.
The Series B-1 Common Warrants will be exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the Pricing Conditions are met, the Warrant Stockholder Approval will not be required and the Series B-1 Common Warrants will be exercisable on the Initial Exercise Date , at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below).

#### Exercise Limitations.
We may not effect the exercise of any Series B-1 Common Warrant, and a holder will not be entitled to exercise any portion of any Series B-1 Common Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% or 9.99% (at the election of the holder) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise. However, any holder of a warrant may increase or decrease such percentage upon at least 61 days’ prior written notice from the holder to us, provided that such percentage in no event exceeds 9.99%.

<div align='center'>23</div>

#### Cashless Exercise.
If, at the time a holder exercises its Series B-1 Common Warrants a registration statement registering the issuance of the shares of Common Stock underlying such Series B-1 Common Warrants under the Securities Act is not then effective or available for the issuance of such shares, or the prospectus contained therein is not available